PT  - JOURNAL ARTICLE
AU  - Zhaolu Xie
AU  - Wei Wu
AU  - Haiyan Xing
AU  - Yongqing Cai
AU  - Xianfeng Wang
AU  - Jianhong Chen
TI  - Bradycardia associated with pegylated liposomal doxorubicin administration: a case report
AID  - 10.1136/ejhpharm-2015-000817
DP  - 2017 Mar 01
TA  - European Journal of Hospital Pharmacy
PG  - 128--130
VI  - 24
IP  - 2
4099  - http://ejhp.bmj.com/content/24/2/128.short
4100  - http://ejhp.bmj.com/content/24/2/128.full
SO  - Eur J Hosp Pharm2017 Mar 01; 24
AB  - The cardiotoxicity of doxorubicin is dose dependent and progressive, but its mechanisms remain unclear. Measures to prevent the cardiotoxicity of doxorubicin have had limited success. We report here on a patient who had received intravenous infusion of pegylated liposomal doxorubicin and developed sinus bradycardia despite the prior administration of the iron-chelating agent, dexrazoxane. The adverse effect of pegylated liposomal doxorubicin might be due to the difference in metabolic related genes for anthracyclines. Therefore, monitoring the cardiac condition of patients who receive doxorubicin treatment, even at low doses, is highly recommended.